Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant with the company since April 2023 and is now a permanent employee. In her new role, she will focus on the CE marking of pHyph and initiate the commercial-scale production of…
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners and new investors exceeded the board’s mandate, and an extraordinary general meeting resolved a directed issue to include the oversubscription of SEK 13 million. In total, Gedea…
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola holds a degree in business adminsitration from Lund University and has over 25 years of experience in the life science industry. His previous roles include CFO positions at Pharmiva…
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment…
The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of this year.
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins Lund, Sweden, November 15, 2023: Gedea Biotech today announced that it has raised 1.5 MEUR (16,5 MSEK) to initiate and accelerate clinical trial activities supporting pHyph™ applicable for…
Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis
This pivotal study aims to confirm the safety and efficacy of pHyph in treating and preventing BV recurrence Patient recruitment will now be initiated and 5 Swedish clinics are planned to attend Previous studies in BV have demonstrated pHyph to have a BV cure rate in line with antibiotics on the…
Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections
Further strengthens Gedea Biotech’s broad patent portfolio pHyph has demonstrated a superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Additionally, unlike antibiotics, pHyph will not promote antimicrobial resistance Lund, Sweden, September…
Making a difference to women worldwide
Gedea Biotech has developed the world’s first antibiotic-free treatment to both treat and prevent bacterial vaginosis. The treatment is called pHyph, and is a vaginal tablet that has shown a medical effectiveness in treating bacterial vaginosis in line with antibiotics on the market, but with a…
Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch
Lund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for: An ongoing proof-of-concept study for the treatment of…